Novan, Inc. - NOVN
About Gravity Analytica
Recent News
- 01.13.2026 - Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance
- 01.05.2026 - Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice
- 12.23.2025 - Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn
- 12.04.2025 - Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%
- 12.02.2025 - Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
- 11.13.2025 - Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results
- 11.07.2025 - Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
- 11.05.2025 - Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025
- 10.09.2025 - Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum
- 09.08.2025 - Pelthos Therapeutics to Participate in Upcoming September Investor Conferences
Recent Filings
- 05.01.2024 - POS AM Post-Effective amendments for registration statement
- 05.01.2024 - EFFECT Notice of Effectiveness
- 05.01.2024 - POS AM Post-Effective amendments for registration statement
- 05.01.2024 - EFFECT Notice of Effectiveness
- 05.01.2024 - EFFECT Notice of Effectiveness
- 05.01.2024 - POS AM Post-Effective amendments for registration statement